6-K: Jemperli Plus Chemotherapy Application Accepted for Review by the European Medicines Agency to Expand Use to All Patients with Primary Advanced or Recurrent Endometrial Cancer
6-K: Jemperli Plus Chemotherapy Application Accepted for Review by the European Medicines Agency to Expand Use to All Patients with Primary Advanced or Recurrent Endometrial Cancer
Jemperli Plus化療的申請已接受歐洲藥品管理局的審查，以便將使用範圍擴大到所有原發性晚期或複發性子宮內膜癌患者
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。